Regulatory Approval Status: Manufactured under GMP conditions as a registered pharmaceutical intermediate/API; supplied with DMF and Certificate of Analysis support, not marketed as a standalone finished drug product
Indication: Benzimidazole anthelmintic (5-chloro-6-(2,3-dichlorophenoxy)-2-methylthio-1H-benzimidazole, C14H9Cl3N2OS, MW 359.66) used since 1983 to control Fasciola spp. (liver fluke) infections
Leave your rating & comment